Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Contraception for the perimenopausal patient.

G V Upton

    Obstetrics and Gynecology Clinics of North America
    |March 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Venlafaxine in the treatment of premenstrual dysphoric disorder.

    Obstetrics and gynecology·2001
    Same author

    The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.

    Journal of clinical psychopharmacology·1998
    Same author

    Contraception for the transitional years of women older than 40 years of age.

    Clinical obstetrics and gynecology·1992
    Same author

    Lipids, cardiovascular disease, and oral contraceptives: a practical perspective.

    Fertility and sterility·1990
    Same author

    The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.

    The Yale journal of biology and medicine·1989
    Same author

    The contraceptive and hormonal requirements of the premenopausal woman: the years from forty to fifty.

    International journal of fertility·1986
    Same journal

    Bridging Science and Practice in Gender-Affirming Care: A Compendium for Gynecologists.

    Obstetrics and gynecology clinics of North America·2026
    Same journal

    Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care.

    Obstetrics and gynecology clinics of North America·2026
    Same journal

    Evaluation and Management of the Pediatric Gender-Diverse Patient.

    Obstetrics and gynecology clinics of North America·2026
    Same journal

    Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.

    Obstetrics and gynecology clinics of North America·2026
    Same journal

    Updates on Breast Cancer Screening and Special Considerations for Transgender Men and Women.

    Obstetrics and gynecology clinics of North America·2026
    Same journal

    Contraceptive Needs of the Transmasculine Patient.

    Obstetrics and gynecology clinics of North America·2026
    See all related articles

    Combination hormone replacement therapy is essential for women over 40, requiring progestogen to prevent endometrial hyperplasia and reduce cancer risk. For premenopausal women, therapy must also offer contraception, though ideal products are lacking.

    Area of Science:

    • Reproductive endocrinology
    • Menopause management
    • Pharmacology

    Background:

    • Hormone replacement therapy (HRT) is crucial for women over 40.
    • Estrogen-only therapy is insufficient and carries risks.
    • Progestogen is necessary for endometrial protection, breast cancer risk reduction, and bone health.

    Purpose of the Study:

    • To highlight the necessity of combination estrogen/progestogen therapy for women over 40.
    • To emphasize the dual role of HRT in therapeutic benefits and contraception for premenopausal women.
    • To address the current gap in ideal low-dose combination products.

    Main Methods:

    • Review of existing clinical data and evidence on hormone replacement therapy.
    • Analysis of the risks and benefits of estrogen-only versus combination therapy.
    Keywords:
    Biological Aging--womenBiologyContraceptionContraceptive AgentsContraceptive Agents, FemaleContraceptive Agents, ProgestinEndocrine SystemEndometrial EffectsEndometriumEstrogens--therapeutic useFamily PlanningGenitaliaGenitalia, FemaleHormonesLipid Metabolic EffectsLipidsMenopauseMetabolic EffectsPhysiologyProgestational Hormones--pharmacodynamicsProgestational Hormones--therapeutic useReproductionUrogenital SystemUterus

    Related Experiment Videos

  • Evaluation of contraceptive needs in premenopausal women undergoing HRT.

    • Main Results:

    • Combination estrogen/progestogen therapy is mandatory for women over 40.
    • Progestogen inclusion prevents endometrial hyperplasia, lowers breast cancer risk, and preserves bone density.
    • Lack of ideal low-dose combination products leads to continued use of separate contraceptives in some cases.

    Conclusions:

    • Combination HRT is essential for women over 40, providing therapeutic benefits and potentially contraception.
    • Further development of ideal low-dose combination products is needed to meet the combined needs of women during perimenopause.
    • Physicians currently manage contraceptive needs separately when suitable products are unavailable.